Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. [electronic resource]
Producer: 20120823Description: 1434-42 p. digitalISSN:- 1879-0852
- Age Factors
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Comorbidity
- Deoxycytidine -- administration & dosage
- Erlotinib Hydrochloride
- Female
- Humans
- Male
- Middle Aged
- Multivariate Analysis
- Neoplasm Metastasis
- Outcome Assessment, Health Care
- Pancreatic Neoplasms -- complications
- Placebos
- Proportional Hazards Models
- Protein Kinase Inhibitors -- administration & dosage
- Quinazolines -- administration & dosage
- Risk
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.